Tradestie Institutional Equity Comparison Engine

ABUS vs DAAQU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while DAAQU counters with relative strength in Momentum & Technical. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus DAAQU at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABUS sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against DAAQU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ABUS
ABUS 10.2x vs DAAQU N/M Fwd P/E
Growth & Margin Winner ABUS
Op Margin 80.1% vs N/A ยท YoY -43.5% vs N/A
Momentum & Technical Winner DAAQU
1Y -8.5% vs +1.8% ยท 52W Pos 29% vs 70%
Options & Structure Winner ABUS
CONSOLIDATION (11th %ile IV) vs UNCLASSIFIED (N/A IV)
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.07
-0.97% 1D
Market Cap $627.7M
1M Return -2.63%
1Y Return -8.54%
Forward P/E 10.2x
Unified AI Score
50.6 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 68.0 Mom 53.7
DAAQU NASDAQ
Digital Asset Acquisition Corp. Units
Blank Checks
$10.58
+0.09% 1D
Market Cap N/A
1M Return +0.28%
1Y Return +1.83%
Forward P/E N/M
Unified AI Score
45.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABUS -8.54% DAAQU +1.83% Spread: +8.78 pp (DAAQU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABUS TTM Op. Margin: 80.1% DAAQU TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs DAAQU. Trailing 12-month operating profitability (ABUS 80.1% vs DAAQU N/A) and valuation multiples (ABUS 10.2x vs DAAQU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABUS (9) vs DAAQU (1)
Institutional Metric ABUS DAAQU Criterion Row Winner
Market Capitalization Scale $627.7M N/A Larger Scale ABUS
Trailing P/E Ratio Valuation 3.7x N/M Lower Multiple ABUS
Forward P/E Ratio Valuation 10.2x N/M Lower Multiple ABUS
Revenue Growth (YoY) Growth -43.5% N/A Higher Growth ABUS
Operating Margin (TTM) Profitability 80.1% N/A Higher Margin ABUS
Net Profit Margin Profitability 121.2% N/A Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency 269.6% N/A Higher ROE ABUS
52-Week Range Position Momentum 29% ($4โ€“$5) 70% ($7โ€“$12) Stronger Trend DAAQU
Beta / 30D Volatility Risk Regime 1.10ฮฒ ยท 48% Vol -0.36ฮฒ ยท 150% Vol Lower Realized Risk ABUS
Unified Institutional Score Composite Signal 50.6 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite ABUS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABUS vs DAAQU Buy Guide
ABUS CONSOLIDATION
95d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DAAQU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DAAQU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABUS nor DAAQU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.